Samiksha Jaiswal

AVN 211

Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
ChemSpider  26387125
Formula  C15H15N3O2S2
3D model (Jmol)  Interactive image
ChEMBL  CHEMBL1668500
Molar mass  333.42 g·mol
AVN-211

AVN-211 (CD-008-0173) is a drug which acts as a highly selective 5-HT6 receptor antagonist and is under development by Avineuro Pharmaceuticals for the treatment of schizophrenia. In early 2011, it successfully completed phase IIa clinical trials, with benefits on positive symptoms and some procognitive effects observed, and in mid 2013, phase IIb clinical trials for schizophrenia began. Avineuro Pharmaceuticals has also expressed intention to start clinical trials of AVN-211 for Alzheimer's disease in 2015.

References

AVN-211 Wikipedia


Similar Topics
Zur Hölle mit den Paukern
Natalia Málaga
Un Jin Moon
Topics